

HeraMED accesses unique pregnancy database to strengthen OrionAI

- ~90,000 high quality, annotated, digital pregnancy monitoring records received from Mayo clinic as part of the collaboration agreement.
- Progresses the Orion AI project and enables increased efficacy via mass data input to OrionAI algorithm
- Data cross referenced with ancillary birth and anonymised patient files – to strengthen the algorithm’s accuracy and machine learning capabilities ‘
- Renowned data scientist and machine learning expert, Uri Merhav joins HeraMED to lead the develop algorithm and extensions

Medical technology company, **HeraMED Limited (ASX:HMD)** (“HeraMED” or the “Company”) advises that it has received ~90,000 pregnancy records from R&D collaborator the Mayo Clinic, This is a key step to progress the next stage of the commercial development of the OrionAI platform.

HeraMED secured a unique access to an industry leading digital pregnancy monitoring database, this will allow expedited solution development and strengthen OrionAI’s machine learning functionality.

OrionAI is HeraMED’s cloud based, machine learning software-as-a-service (SaaS) platform, being developed in collaboration with the Mayo Clinic. OrionAI plans to utilise big data and analyse thousands of pregnancy records in real time to enable potentially unprecedented analysis accuracy. The platform aims to detect pregnancy complications early, which will potentially have a significant impact on pregnancy. The solution may also reduce costs for hospitals and clinics, as well as optimise the efficiency of medical professionals.

The data encapsulates over ten years of activity at Mayo and was extracted over several months from the Mayo Clinic’s historical records by its Artificial Intelligence and Machine Learning experts. Records will be housed on a HIPAA (Health Insurance Portability and Accountability Act) compliant secure server, ensuring the data is well protected and secured.

The records are high quality and comprehensive and include cardiotocography (CTG) data or birth stage monitors, as well as nonstress test (NST) data, encompassing earlier stages of pregnancy. This is advantageous to HeraMED, as NST data allows for the development of OrionAI algorithm extensions to analyse earlier stages of pregnancy. This will allow HeraMED to incorporate OrionAI with HeraCARE, providing a more homogeneous solution.

Having a large volume of records, which includes the results of the majority of pregnancies will allow OrionAI’s machine learning functionalities to educate the algorithm to gain a better understanding of the correlations between physiological measurements and the effects these have on the pregnancy journey and the health of a baby.

To ramp up development, HeraMED has appointed leading, US-based data scientist, Uri Merhav (M.Sc in Physics, TAU, Magna Cum Lauda) as OrionaAI chief architect. Mr Merhav was former staff machine learning engineer at LinkedIn and author of seven registered machine learning patents. He is a machine and deep learning expert and was fundamental in creating HeraMED’s first foetal heart rate algorithm. Uri joins HeraMED’s professional innovation team, which includes Dr Arturo Weschler MD, Oren Kapach (PhD Computer Science), Roei Tov (PhD Computer Science) and Yael Kierson (M.Sc. Medical Physics).

CEO and Co-founder Mr David Groberman said: “This massive database provides HeraMED with a unique and strategic digital pregnancy monitoring records. This will assist our experts in the efforts of turning OrionAI into the most advanced AI based diagnostic tool for pregnancy wellbeing analysis. Uri is considered a leading expert and one of the brightest minds in machine learning, bringing him to lead the company’s AI initiatives, with his unique capabilities and proven knowledge is of great value.

“As additional datasets are planned to be implemented, OrionAI will only become stronger, smarter and more resilient. We believe it will provide improved pregnancy monitoring solutions for expecting mothers, as well as allow medical professionals to optimise their time and become better patient advocates.

“We look forward to continuing our work with Uri and the Mayo Clinic and providing updates to shareholders as developments progress.”




Image one: OrionAI interface showing sample case studies

This announcement has been approved by the Board of HeraMED Limited.

-ENDS-

HeraMED Limited
CEO and Co-Founder
David Groberman
M: +972-52-6991188
E: david@hera-med.com

Company Secretary
Stephen Buckley
T: +61 (0) 8 6189 1155
E: stephen@hera-med.com

Released through: Henry Jordan, Six Degrees Investor Relations, +61 431 271 538

About HeraMED Limited (ASX:HMD):

HeraMED is an innovative medical Data and Technology company leading the digital transformation of prenatal care. HeraMED utilises the digital health ecosystem including clinical home monitoring devices, cloud computing, artificial intelligence, big data and digital social networking to reshape the Doctor/Patient relationship. The Company is revolutionising the pregnancy experience by empowering personalised, continuous and proactive home monitoring, to deliver better care at a lower cost. Keeping pregnant mothers engaged, informed and well-supported provides reassurance and peace of mind while allowing the healthcare providers to work at their highest levels of ability and enabling early detection of potential risks.